Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 501 participants.
Also called NCT02597127
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 501 participants
- Sponsor
- Registry
-
NCT02597127
-
- Other papers using this trial's data
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, Netherlands, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02597127. Randomized; double masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2017-06-07 (actual). Results posted on 2019-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
- Acronym
- ORION-1
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Familial Hypercholesterolemia
- Condition
- Diabetes
- Intervention (Drug)
- ALN-PCSSC
- Intervention (Drug)
- Normal Saline
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct02597127- Content hash
c95650a58cd08a10e9d66ff5391fb614e10ad9298bdb8da17455528133dfa9f0